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Abstract
Background: Infective endocarditis is an uncommon but serious infection, where evidence for giving antibiotic
prophylaxis before invasive dental procedures is inconclusive. In England, antibiotic prophylaxis was offered
routinely to patients at risk of infective endocarditis until March 2008, when new guidelines aimed at reducing
unnecessary antibiotic use were issued. We investigated whether changes in infective endocarditis incidence could
be detected using electronic health records, assessing the impact of inclusion criteria/statistical model choice on
inferences about the timing/type of any change.
Methods: Using national data from Hospital Episode Statistics covering 1998–2017, we modelled trends in infective
endocarditis incidence using three different sets of inclusion criteria plus a range of regression models, identifying
the most likely date for a change in trends if evidence for one existed. We also modelled trends in the proportions
of different organism groups identified during infection episodes, using secondary diagnosis codes and data from
national laboratory records. Lastly, we applied non-parametric local smoothing to visually inspect any changes in
trend around the guideline change date.
Results: Infective endocarditis incidence increased markedly over the study (22.2–41.3 per million population in 1998
to 42.0–67.7 in 2017 depending on inclusion criteria). The most likely dates for a change in incidence trends ranged
from September 2001 (uncertainty interval August 2000–May 2003) to May 2015 (March 1999–January 2016),
depending on inclusion criteria and statistical model used. For the proportion of infective endocarditis cases associated
with streptococci, the most likely change points ranged from October 2008 (March 2006–April 2010) to August 2015
(September 2013–November 2015), with those associated with oral streptococci decreasing in proportion after the
change point. Smoothed trends showed no notable changes in trend around the guideline date.
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Conclusions: Infective endocarditis incidence has increased rapidly in England, though we did not detect any change
in trends directly following the updated guidelines for antibiotic prophylaxis, either overall or in cases associated with
oral streptococci. Estimates of when changes occurred were sensitive to inclusion criteria and statistical model choice,
demonstrating the need for caution in interpreting single models when using large datasets. More research is needed
to explore the factors behind this increase.
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Background
Infective endocarditis is an uncommon but serious infec-
tion, for which the evidence for giving antibiotic prophy-
laxis to people undergoing invasive dental procedures is
inconclusive. In March 2008, the National Institute for
Health and Care Excellence (NICE) issued guidelines
recommending that antibiotic prophylaxis during inva-
sive dental procedures should no longer be routinely of-
fered to people at risk of infective endocarditis in
England [1]. This was in contrast to American Heart As-
sociation (AHA) [2] and European Society of Cardiology
(ESC) [3] guidelines issued around the same time, which
continued to recommend antibiotic prophylaxis in cer-
tain high-risk cases, e.g., patients with prosthetic heart
valves or who had had infective endocarditis previously.
Although much research on the impact of guideline
changes on the incidence of infective endocarditis has
been conducted internationally [4–15], and in particular
a study in England which showed an increase in cases
following the NICE guideline change [6], no consensus
has been reached, and in a 2016 update to their guide-
lines [16] NICE reaffirmed their previous position, while
clarifying that doctors and dentists should still apply
their clinical judgement on a case by case basis.
A recent study of ICD-10 (International Classification of
Diseases, Tenth Revision) diagnosis codes used to represent
infective endocarditis cases at two large English hospital
trusts [17] concluded that the inclusion criteria for observa-
tional studies using electronic health records (EHRs) need
to be selected very carefully, as, even when specific diagnos-
tic codes are chosen with care, individual records may still
not always represent confirmed clinical cases. To build on
this, we conducted a range of analyses using national EHR
data on infective endocarditis in England, in particular in-
vestigating whether changes in incidence could be detected
around the change in NICE guidelines or at other times,
and assessing the impact of inclusion criteria and statistical
model choice on inferences drawn about timing and types
of change. We also linked EHR data to national microbiol-
ogy data to analyse trends in the microorganisms isolated
from blood during each infective endocarditis episode, in
particular those genera or species known to commonly col-
onise the oropharynx, which to our knowledge has not pre-
viously been done in England.
Methods
Incidence of infective endocarditis
To measure national incidence of infective endocarditis
between April 1998 and March 2017 inclusive, we used
data from the Admitted Patient Care dataset from Hos-
pital Episode Statistics (HES), which contains details of all
inpatient admissions to NHS hospitals in England, with
clinical diagnoses recorded using ICD-10 codes. In HES,
diagnosis codes are recorded against finished consultant
episodes, so after identifying all episodes that contained a
code for infective endocarditis, we concatenated adjoining
episodes (including where patients transferred between
different providers) into continuous inpatient spells [18]
(also known as “superspells”). To identify incident cases of
infective endocarditis, we used three different inclusion
criteria (designated A–C), reflecting possible differences in
sensitivity:
 Criteria A: At least one of the ICD-10 codes: I33.0,
I33.9, I39.0, I39.8, I01.1, B37.6, or T82.6 in any diag-
nosis field, or I38 in the primary diagnosis field, in
any episode in a superspell, where the patient was
not discharged alive within 2 days, and excluding
any readmissions within 30 days (using the HES pa-
tient ID as the patient identifier)
 Criteria B: ICD-10 code I33.0 in the primary diagno-
sis field, in any episode in a superspell, where the pa-
tient was not discharged alive within 2 days,
excluding any readmissions within 30 days (using the
HES patient ID as the patient identifier), and exclud-
ing elective admissions
 Criteria C: ICD-10 code I33.0 in the primary diagno-
sis field, in any episode in a superspell, excluding
those with an admission method of “Elective - wait-
ing list”
Criteria A and B were shown by Fawcett et al. [17] to
represent the true number of infective endocarditis cases
more accurately than simpler criteria, with Criteria A
maximising sensitivity plus positive predictive value
(PPV) and Criteria B maximising specificity plus PPV,
while Criteria C was that employed by Dayer et al. [6],
the most prominent prior study based on national HES
data.
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Using annual population estimates from the Office for
National Statistics [19], we applied two different
methods to control for changes in the underlying popu-
lation: (1) by dividing the monthly cases by the total
population of England (using linear interpolation be-
tween each annually estimated figure to avoid sudden
jumps in the denominator) and (2) by direct standardisa-
tion to the (5-year) age and sex distribution of England
in 1998.
We also calculated incidence of infective endocarditis
cases in high-risk individuals (out of the same under-
lying denominator populations), defining “high risk” by
the AHA [2] and ESC [3] guidelines, i.e. cases where
there had been a previous admission for infective endo-
carditis (using the same case definitions within each cri-
teria) or pre-existing prosthetic valve or congenital heart
disease (using the same coding criteria implemented by
Dayer et al. (Additional file 1: Table S1)), and separately
in cases with current or previous codes reflecting illicit
drug use (F11 (opioids), F12 (cannabinoids), F14 (co-
caine), F19 (multiple or other psychoactive substances),
T40 (poisoning by narcotics/psychodysleptics)). (While
it is specifically intravenous drug use that results in an
increased risk for endocarditis, there are currently no
diagnosis codes that directly represent this, and there-
fore illicit drug use was used as a proxy.) Since these
methods are dependent on data from previous admis-
sions, we only calculated incidence from year end 1999
onwards, to allow for a “burn-in” time of one calendar
year.
Causal organisms
We identified potential causal organisms using secondary
diagnosis codes that were present in the same consultant
episode(s) as the code(s) for infective endocarditis within a
superspell, and categorised these into three overall groups:
Streptococcus species, Staphylococcus species, and other/
unnamed species (Additional file 1: Table S2). If more
than one organism code was present in a superspell (e.g. if
a superspell consisted of multiple episodes with different
secondary organism codes and/or an episode included
more than one organism code), we included them all.
Since ICD-10 codes do not distinguish between infec-
tion with oral and non-oral streptococci, we further
matched the HES records to microbiological test results
in Public Health England’s Second Generation Surveil-
lance System (SGSS), which receives microbiology re-
sults from > 98% of hospital laboratories in England.
Organisms from blood specimens recorded in SGSS
were matched to episodes in HES that contained an in-
fective endocarditis diagnosis code based on NHS num-
ber and specimen date between 7 days before episode
start date up to episode end date, by the data manager
at Public Health England who had authorisation to view
personal identifiable data (under Regulation 3 of the
Health Service (Control of Patient Information) Regula-
tions 2002). If more than one SGSS record was matched
within a superspell, we included them all. We considered
the organisms from SGSS and HES to be in agreement
for an infective endocarditis case if at least one organism
from each source was present and belonged to the same
overall group (as defined above). We modelled overall
trends in organism group proportions and in SGSS/HES
agreement using Poisson regression (or negative bino-
mial regression when there was evidence of overdisper-
sion) with the following denominators as exposure
variables: for organisms based on HES diagnosis codes,
we controlled for the denominator of cases with any or-
ganism coded in HES; for SGSS/HES agreement, we
controlled for the denominator of cases that had any or-
ganism present both in SGSS and in HES; and for organ-
isms based on SGSS records, we controlled for the
denominator of cases with any match to an organism
record in SGSS. Models using SGSS-linked data were re-
stricted to dates after October 2002, when there were
consistently at least 10 infective endocarditis cases
matched to an SGSS organism per month. We further
categorised SGSS organisms into nine subgroups: oral
streptococci, pyogenic streptococci, Group D strepto-
cocci, other streptococci, HACEK (a group of fastidious
Gram-negative bacteria that are a known cause of infect-
ive endocarditis) [20], enterococci, Staphylococcus aur-
eus, coagulase-negative staphylococci, and “Other”
(Additional file 1: Table S3).
Temporal association between infective endocarditis
incidence and change in prophylaxis guideline
Date-based interventions are often assessed using an
interrupted time-series analysis, comparing the trend in
incidence before and after the intervention date. How-
ever, when the overall trend is non-linear, this method-
ology is biased towards finding a positive result (see
Additional file 1: Table S4). To avoid this, we instead fit-
ted a range of models to identify those that fitted the
data the best, to investigate the evidence supporting a
change in incidence of infective endocarditis following
the guideline change as opposed to at other time points.
We systematically fitted piecewise linear Poisson (or
negative binomial) regression models to the raw monthly
cases (with and without adjusting for total population as
an exposure variable), as well as to the standardised
monthly cases. We fitted four different types of model:
(1) a single overall trend, (2) two (potentially) different
trends before and after a single change point, (3) two
(potentially) different trends before and after a single
change point plus a step change at that point, (4) a sin-
gle step change only, with no trend either before or after
the change. We used a grid search algorithm,
Quan et al. BMC Medicine           (2020) 18:84 Page 3 of 17
considering single change points at each month from
October 1997 to September 2016 inclusive, and selecting
the best-fitting model and “month of change” by Akaike
Information Criterion (AIC) [21]. Uncertainty intervals
were estimated as the range of dates within a difference
in AIC of < 3.84 from the model with the best-fitting
date, taking the minimum and maximum dates even if
there were non-contiguous ranges of dates within this
threshold. The same range of models were fitted to the
monthly proportion of infective endocarditis cases that
contained a HES streptococcal code (out of the total
number of infective endocarditis cases that contained
any HES organism code), as well as to the monthly pro-
portion of infective endocarditis cases that matched to
an oral Streptococcus in SGSS (out of the total number
of infective endocarditis cases that matched to any organ-
ism record in SGSS, and restricting this latter search to
change points between April 2003 and September 2016
(since data prior to October 2002 were excluded from the
models due to low numbers of cases matching to SGSS
(see above)). These proportions were modelled as monthly
cases associated with the particular type of organism
against time as the independent variable, with the relevant
denominator included as an exposure variable.
Additionally, instead of making an a priori assumption
of fixed incidence rates before and after a single change
point, we applied a non-parametric LOWESS smoother
[22] to visually inspect trends. We compared these to what
would be expected under a hypothesis that dental prophy-
lactic antibiotic prescribing was protective against the de-
velopment of infective endocarditis (both for total cases
and for the proportion of cases linked to oral strepto-
cocci), against an assumed background of linearly increas-
ing cases unrelated to dental prophylactic antibiotic
prescribing. To confirm that the change in guideline re-
sulted in reduced dental prophylactic antibiotic prescrib-
ing, we downloaded annual data on two types of
prescriptions known to be used almost exclusively [6] for
dental prophylaxis in the community (3 g doses of amoxi-
cillin and 600mg doses of clindamycin) from NHS Digital
[23]. We plotted annual numbers of 3 g amoxicillin doses
only, as it was not possible to distinguish 600mg doses of
clindamycin (as opposed to other dose strengths) from the
data, although it has previously been shown that the latter
form only around 25% or less of prophylactic prescribing
and follow the same pattern as 3 g amoxicillin doses [6].
All analyses were conducted using Stata v15.1 (StataCorp).
Results
Incidence of infective endocarditis
The incidence of infective endocarditis in England in-
creased between April 1998 and March 2017, irrespect-
ive of which of the three criteria we used to measure it
(Fig. 1a). Annual numbers of cases and incidence rates
can be seen in Table 1. Criteria A (optimised for sensi-
tivity/PPV) produced the highest numbers of cases over-
all, while Criteria B (optimised for specificity/PPV)
produced the lowest numbers of cases. The trends using
Criteria A and B appeared very similar throughout the
entire period, whereas the trend based on Criteria C
(used by the largest prior English study) appeared to in-
crease more rapidly compared to the other two Criteria
from around 2010 onwards (Fig. 1b). Controlling for
changes in population attenuated the yearly increases
but did not change the overall trend pattern (Fig. 1c,
Additional file 2: Figure S1).
High-risk individuals comprised 13,581/50570 (27%),
7286/28851 (25%), and 12,873/35752 (36%) cases for cri-
teria A, B, and C respectively. Incidence of infective
endocarditis in “high-risk” individuals also increased
steadily (Fig. 2a), with the same divergence of Criteria C
from the other two Criteria in around 2010 (Fig. 2b). In-
dividuals with a history of illicit drug use comprised
3927/50570 (8%), 2590/28851 (9%), 3106/35752 (9%)
cases for criteria A, B, and C respectively. Numbers of
infective endocarditis cases in these individuals followed
a slightly different pattern, increasing up until around
2008, dipping slightly until 2011, then increasing again
more rapidly to levels in 2017 that were more than
double the number at the earlier peak in 2008 (Fig. 2b).
Trends in cases when excluding these individuals were
similar to trends in overall cases (Additional file 2: Fig-
ure S2).
Causal organisms
Considering Criteria B (i.e. optimised for specificity/
PPV) first, since this minimises inclusion of false-
positive cases, 19,290/28851 (67%) infective endocarditis
cases contained a secondary diagnosis code for an organ-
ism in HES. The proportion of infective endocarditis
cases with a secondary diagnosis code for an organism
increased from around 40% in 1997 to roughly 75% in
2011, plateauing thereafter (Fig. 3a). Out of those with
an organism coded, 9533 (49%) contained a code for
streptococcal species (including mixtures) and 8244
(43%) contained a code for staphylococcal species (in-
cluding mixtures), with no evidence of overall trend
across the time period for these proportions (annual in-
cidence rate ratio (aIRR) = 1.00 (95% CI 1.00, 1.00), p =
0.56; aIRR = 1.00 (0.99, 1.00), p = 0.06 respectively)
(Fig. 3b). A total of 3908 (20%) cases contained a code
for a different or unnamed organism (including mix-
tures), and this proportion increased over the period
(aIRR = 1.05 (1.04, 1.05), p < 0.001). A total of 2250
(12%) cases had a mixture of organism codes, and this
proportion increased over the period (aIRR = 1.05 (1.04,
1.06), p < 0.001) (Fig. 3c), while the proportion of cases
coded exclusively as streptococcal or staphylococcal
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Fig. 1 Monthly cases of infective endocarditis. Different coloured lines represent different inclusion criteria. a Raw cases. b Raw cases after
applying a non-parametric LOWESS smoother. c Effect of applying different methods to adjust for changes in population, shown here for all cases
using Criteria A, but results are similar for all three criteria (see Additional file 2: Figure S1)
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species decreased slightly over time (aIRR = 0.99 (0.99,
0.99), p < 0.001; aIRR = 0.99 (0.99, 0.99), p < 0.001 re-
spectively). Patterns were similar for Criteria A and C
(Additional file 2: Figures S3-S5).
The proportion of Criteria B cases with both an organism
code in HES and a microbiological record in SGSS in-
creased from zero in 2001 to around 50% in 2017 (Fig. 4a).
In cases where an organism was recorded in both HES and
SGSS, 7095/7882 (90%) agreed at the overall group level
(streptococcal, staphylococcal or other/unnamed species),
with a modestly increasing trend over time (aIRR =
1.04 (1.02, 1.05), p < 0.001). Of the 10% (n = 787) of
cases that disagreed, 463 (59%) contained a strepto-
coccal code in HES and matched to an enterococcal
record in SGSS. Of the 2229/19290 (12%) cases where
HES only indicated other/unnamed species, 1188
(53%) did not match to any records in SGSS, 114
(5%) matched to a streptococcal record, 105 (5%) to a
staphylococcal record, and 895 (40%) to other species
(including 506 (23%) enterococci). Again, patterns
were similar for Criteria A and C (Additional file 2:
Figure S6).
Of all Criteria B cases that were matched to an
organism in SGSS, 2855/10715 (27%) were identified as
oral streptococci, and there was no evidence that this
proportion changed over time (aIRR = 0.99 (0.98, 1.00),
p = 0.08) (Fig. 4b). This pattern was similar for Criteria
A and C (Additional file 2: Figure S7), and there was no
qualitative difference in behaviour between different or-
ganism subgroups (Additional file 2: Figure S8).
Fig. 2 Monthly cases of infective endocarditis in individuals identified as high-risk or as illicit drug users. Different coloured lines represent
different inclusion criteria. a Raw cases. b Raw cases after applying a non-parametric LOWESS smoother
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Fig. 3 (See legend on next page.)
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Temporal association between infective endocarditis
incidence and change in prophylaxis guideline
As expected given the non-linear changes in incidence
across the study period (Fig. 1), regression models test-
ing for a difference in trend before and after a fixed date
showed a bias towards a positive result; e.g. for Criteria
A, a statistically significant (p < 0.05) increase in trend
was found after 230 of the 238 possible dates tested
across the period (Additional file 1: Table S4). The eight
non-significant dates were all at the extreme ends of the
study period (and were a consequence of wide confi-
dence intervals due to the small number of data points
at the extreme ends as opposed to the before vs after
trend estimates being closer).
(See figure on previous page.)
Fig. 3 Causative organism based on secondary diagnosis codes in HES, using Criteria B (optimised for specificity/PPV). (For Criteria A and C, see
Additional file 2: Figures S3–5). a Monthly infective endocarditis cases according to corresponding organism codes (in same consultant episode),
along with overall proportion of cases with any organism coded. b Of infective endocarditis cases with an organism code present, proportion
that were coded as streptococcal, staphylococcal, or other/unnamed, including mixtures. c Of infective endocarditis cases with an organism code
present, proportion that were coded exclusively as streptococcal, staphylococcal or other/unnamed, or else with a mixture of codes
Fig. 4 Causative organism based on SGSS, using Criteria B (optimised for specificity/PPV). (For Criteria A and C, see Additional file 2: Figures S6-
S7). a Monthly agreement of SGSS organism compared to HES organism code, based on 3 groups: streptococcal, staphylococcal, other/unnamed.
b Of all infective endocarditis cases that were matched to an organism in SGSS, proportion that were classed as oral streptococci
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When considering the best-fitting models of each type
(see “Methods”), December 2010, July 2011, and June
2011 were identified as the most likely month of change
in incidence trends for Criteria A, B, and C respectively
(34–39months after the guideline change) (Table 2). For
high-risk cases, the most likely month of change was
variously identified as January 2000, September/October
2001, June 2002, or May 2015. Models which allowed
for a different trend both before and after a change point
fitted better than the models which enforced a zero
trend or allowed no change point.
For the proportion of infective endocarditis cases with
a streptococcal diagnosis code in HES (including mix-
tures) out of those with any organism coded, the best-
fitting model for Criteria A was an upward step in Octo-
ber 2008 (IRR = 1.05 (1.02, 1.09), p < 0.01) with zero
trend either side. For Criteria B, the best model was a
downward step in June 2013 (IRR = 0.96 (0.92, 1.00), p =
0.07) with zero trend either side. For Criteria C, the best
model was an upward trend (aIRR = 1.01 (01.00, 1.01),
p = 0.06) until December 2012 where there was a down-
ward step (IRR = 0.88 (0.81, 0.95), p < 0.001), after which
there was another upward trend (aIRR = 1.03 (1.00,
1.05), p = 0.05) (Table 3).
For the proportion of infective endocarditis cases
matched to an oral Streptococcus record in SGSS (in-
cluding mixtures) out of those with any organism identi-
fied in SGSS, the best-fitting model for Criteria A was
an upward trend until December 2008 followed by a
downward trend (aIRR = 1.07 (1.04, 1.11), p < 0.001 until
December 2008, then aIRR = 0.98 (0.96, 0.99), p < 0.001
afterwards). For Criteria B, the best model was a down-
ward step in August 2015 (IRR = 0.84 (0.77, 0.93), p <
0.001) with zero trend either side. For Criteria C, the
best model was an upward trend until June 2012
followed by a downward trend (aIRR = 1.02 (1.00, 1.04),
p = 0.03 until June 2012, then aIRR = 0.94 (0.92, 0.97),
p < 0.001 afterwards) (Table 3).
Antibiotic prophylaxis prescribing dropped dramatic-
ally in 2008 (Fig. 5a). We hypothesised that if antibiotic
prophylaxis were protective against the development of
infective endocarditis, then both the incidence of infect-
ive endocarditis, and particularly cases associated with
oral streptococci, would be a “mirror image” of the pre-
scribing trend, though attenuated and with a possible
delay in effect of 3–6 months (possible incubation period
for infective endocarditis, longer lag periods would ex-
tend the period over which changes occurred, and
shorter periods would reduce it) (Fig. 5b). There was no
discernible change in the smoothed trends for overall
and high-risk infective endocarditis cases in the time
period around the guideline change in March 2008; inci-
dence started increasing from 2010 (Fig. 5c). For the
proportion of infective endocarditis cases associated with
streptococcal organisms, again there was no apparent in-
crease in the smoothed trends around the guideline
change; the proportion with any streptococcal diagnosis
code appeared constant over the entire period, while the
proportion of oral streptococci appeared to increase
gradually and then decrease, but with no clear “peak”
date (Fig. 5d).
Discussion
Cases of infective endocarditis are continuing to increase
in England but this study found no evidence that there
was any change in incidence associated specifically with
the date of withdrawal of dental antibiotic prophylaxis as
opposed to any other arbitrary date within the period of
study. Controlling for population changes attenuated the
increase in infective endocarditis but did not remove it.
Statistical models suggested a wide variety of different
“optimal” dates for a change in incidence trends, ranging
from over 6.5 years before up to 7 years after the date of
the guideline change. Models looking at the proportion
of infective endocarditis cases associated with strepto-
coccal species had optimal change points between 6
months and 7 years after the guideline change; however,
the proportion of infective endocarditis cases associated
specifically with oral streptococci actually decreased after
the change points. While the optimal model for the pro-
portion of Criteria A cases containing any streptococcal
code from HES suggested an upward step in October
2008, there is no reason to believe that this one result is
more informative than the other five results (including
from the two other criteria) that suggested different
dates and types of change point. Had there been a real
change in incidence to detect, we would have expected
there to be a clustering of results around a particular
date and model, but this was not seen. There was also
no discernible change in locally smoothed trends in in-
fective endocarditis cases around the time the guidelines
changed, nor any clear change in the proportion of in-
fective endocarditis cases associated with oral strepto-
cocci. This was despite a clear and dramatic drop in
antibiotic prescribing for dental prophylaxis.
When examining overall incidence trends, the choice
of ICD-10 codes appeared to matter less than the strat-
egy used for identifying incident cases. While the broad
basket of codes used for Criteria A (maximising sensitiv-
ity and PPV) resulted in much higher estimates of inci-
dence, the trend over time was very similar to that for
Criteria B (which only used I330 primary codes and a
similar strategy for identifying incident cases, maximis-
ing specificity and PPV). Contrastingly, there was a
much steeper trend (both in all cases and in high-risk
cases) for Criteria C post-2010 than there was for Cri-
teria A or B. Since both Criteria B and C used the same
ICD-10 codes, the difference in incidence trends is only
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explained by the choice of strategy for identifying inci-
dent cases (i.e. the exclusion of short stays, 30-day read-
missions and all elective admissions for Criteria B,
versus the exclusion of “Elective – waiting list” admis-
sions for Criteria C). Explicit exclusion of readmissions
is particularly important as efforts to reduce length of
stay in English hospitals over the last decade have seen
concurrent increases in readmissions. Alternatively,
some attendances for Outpatient Parental Antibiotic
Therapy, increasingly used to provide long intravenous
antibiotic courses, may have been incorrectly coded as
inpatient admissions, artificially inflating case numbers.
The main strength of this study is the inclusion of
microbiological data from SGSS that distinguishes oral
streptococci from other streptococcal species. Although
the proportion of infective endocarditis cases that could
be matched to a microbiological sample was typically
below 50% and changed considerably over time, the
agreement between the organisms found in SGSS versus
HES was regularly around 90%, suggesting that when
Table 3 Variation in goodness of fit and optimal change point based on different models for the proportion of infective
endocarditis cases associated with streptococcal organisms. For each model type, the month of change which gives the best model
fit is shown, with best overall models shown in bold italics. AIC measures model goodness of fit (the lower the value the better the
fit, within each set of inclusion criteria)
Inclusion criteria Model type AIC Month of change (uncertainty
interval)
Proportion of cases with a HES streptococcal code
(including mixtures), out of all cases with any HES
organism code
Criteria A (Sensitivity/
PPV)
One change in trend, with
step
1494.8 Oct 2008 (Dec 2005–Oct 2015)
One change in trend, no
step
1498.3 Apr 2002 (Oct 1997–Sep 2016)
Single overall trend 1498.7 NA
No trend, with step 1493.4 Oct 2008 (Mar 2006–Apr 2010)
Criteria B (Specificity/
PPV)
One change in trend, with
step
1415.1 Oct 2015 (Aug 2005–Dec 2015)
One change in trend, no
step
1417.0 Sep 2011 (Oct 1997–Sep 2016)
Single overall trend 1416.2 NA
No trend, with step 1413.3 Jun 2013 (Oct 1997–Sep 2016)
Criteria C (Prior study) One change in trend, with
step
1508.4 Dec 2012 (Nov 2012–Oct 2013)
One change in trend, no
step
1516.5 Dec 2010 (Oct 1997–Sep 2016)
Single overall trend 1516.6 NA
No trend, with step 1511.6 Dec 2012 (Apr 1999–May 2016)
Proportion of cases matched to an SGSS oral
streptococcus sample (including mixtures),
out of cases matched to any SGSS organism
sample
Criteria A (Sensitivity/
PPV)
One change in trend, with
step
952.5 Mar 2008 (Mar 2007–Oct 2013)
One change in trend, no
step
951.6 Dec 2008 (Jun 2007–Sep 2012)
Single overall trend 970.4 NA
No trend, with step 960.1 Aug 2015 (Apr 2003–Oct 2015)
Criteria B (Specificity/
PPV)
One change in trend, with
step
894.0 Sep 2013 (Mar 2006–Oct 2015)
One change in trend, no
step
892.9 May 2009 (Jan 2007–Feb 2015)
Single overall trend 902.5 NA
No trend, with step 892.6 Aug 2015 (Sep 2013–Nov 2015)
Criteria C (Prior study) One change in trend, with
step
907.3 Oct 2013 (Mar 2007–Oct 2015)
One change in trend, no
step
906.6 Jun 2012 (May 2007–Jun 2014)
Single overall trend 919.2 NA
No trend, with step 907.0 Sep 2015 (Sep 2013–Nov 2015)
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organism codes are present, they are probably reliable.
(The increase in numbers matched likely reflects add-
itional microbiology laboratories joining SGSS, reducing
variability in estimated agreement over time.) Despite
this, the organisms isolated from a patient with an in-
fective endocarditis episode cannot be guaranteed to be
the cause of the infective endocarditis episode as op-
posed to another co-occurring infection or blood culture
contaminant, which could explain some of the
discrepancies.
One limitation is that, while the numbers of proce-
dures for prosthetic valve replacement and repair have
undoubtedly increased over the last decade, we did not
have access to mortality data and only had HES episodes
that contained endocarditis codes, so were not able to
attempt to estimate how much of the increase could be
explained simply by an increase in the high-risk popula-
tion. However, the upward trend in infective endocardi-
tis incidence is clearly not limited to this group, as it
was still visible in the population with no recorded his-
tory of these procedures (Additional file 2: Figure S2A).
Similarly, as in previous studies, we did not have access
to data on the population actually undergoing invasive
dental procedures to use as a denominator; we
Fig. 5 Temporal association of guideline change and incidence of infective endocarditis. a Annual prescriptions of 3 g amoxicillin dispensed in the
community. Grey bar represents year of guideline change. b Hypothesised trend change in cases of infective endocarditis and in proportion of
infective endocarditis cases linked to oral streptococci, assuming that dental antibiotic prophylaxis is protective of infective endocarditis (based on an
assumed background of linearly increasing cases unrelated to oral prophylaxis). The solid line demonstrates an immediate effect, the dotted line
demonstrates a delayed effect (assuming an incubation period of around 6months—longer incubation periods would extend the delay in effect, and
shorter incubation periods would move it closer to the solid line). c Actual trend change in cases of infective endocarditis after applying a non-
parametric LOWESS smoother. d Actual trend change in proportion of infective endocarditis cases matched to a streptococcal organism code
(including mixtures), after applying a non-parametric LOWESS smoother. Dotted vertical lines represent date of guideline change
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attempted to assess the potentially dental-exposed popu-
lation by looking at cases of infective endocarditis asso-
ciated with organisms that are known to reside in the
mouth (in particular oral streptococci) and did not find
any increase in these cases.
A further strength of the study is the variety of statis-
tical methods used, which showed how interpretation
can be influenced by choice of model and/or coding cri-
teria. However, another limitation is that our models
only allowed for at most one change in trend, albeit with
and without an additional increase in incidence, and
were restricted to log-linear associations with time.
While in theory other, more complex models might have
fitted the data better, non-parametric smoothed trends
suggest our modelling strategy was not unreasonable.
Since our identification of high-risk cases was dependent
on coding in earlier years, it is possible that cases in earl-
ier periods (where there were fewer years of previous
codes available) are underestimated compared to cases
in later years. However, this would create a bias towards
finding an increase in incidence after the guideline
change and therefore does not affect our conclusion that
increases could not be specifically linked to timing of
guideline change. Another more general limitation is
that since data from EHRs such as HES are collected
principally for administrative reasons rather than for re-
search, they are potentially subject to (and biased by) op-
erational factors that we may simply not be aware of.
The most recent comparable study using English data
was published in 2015 [6] and reported an increase in
the incidence rate of infective endocarditis following
publication of the NICE guidelines. However, when we
used different case definitions based on a recent study
[17] and different statistical methods which identify the
most likely date that trends changed, we found a wide
range of likely dates for a change in incidence trends,
leading us to conclude that there is no evidence for a
direct link with the change in guidance in 2008. Al-
though Criteria C implements the inclusion as reported
in the earlier study [6], we found small differences in es-
timated incidence compared to this publication and
found much higher and more stable coverage of second-
ary ICD-10 codes for organisms than previously re-
ported, despite theoretically using the same underlying
HES data. Studies from other countries have reported
varying results, some seeing overall increases in infective
endocarditis [10–13] and some not [4, 5, 7–9, 14, 15],
though those that we are aware of which looked specific-
ally at cases associated with oral streptococci did not re-
port an increase after guideline changes [7, 8, 15]. It is of
course still possible that there is an increased risk of de-
veloping infective endocarditis after an invasive dental
procedure [24], but the vast majority of cases appear to
be unrelated to such procedures, and the efficacy of
antibiotic prophylaxis in preventing cases is still
inconclusive.
Conclusions
We find no evidence that the change in guidelines for
dental antibiotic prophylaxis has increased the incidence
of infective endocarditis in England, since neither the
trends in incident cases nor in the proportion of cases
associated with oral streptococci (i.e. cases more likely
to be associated with invasive dental procedures) ap-
peared to correspond to the clear change in dental anti-
biotic prescribing. Statistical tests for changes in trend
were highly statistically significant across a wide range of
time points, but the optimal time of change identified
was sensitive to differences in inclusion criteria and
choice of model. Focussing on evidence for changes after
vs before a single time point in one outcome with one
analysis method may be problematic in large ecological
studies of this type. Non-parametric smoothing can be
used as a helpful “sense check”.
Large observational studies based on EHRs are becom-
ing increasingly common and are attractive given their
high power and relatively low cost. However, such stud-
ies need to be conducted very carefully, including the
use of extensive sensitivity analyses as demonstrated
here, because their higher power makes the finding of
statistically significant results much more likely. Al-
though we find no evidence that the withdrawal of den-
tal antibiotic prophylaxis has increased cases of infective
endocarditis, we do find that infective endocarditis has
continued to increase rapidly in England, with incidence
roughly doubling over the 20 years of the study. Further
research should focus on determining the true cause of
this increase.
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